Endometrial cancer in a renal transplant recipient: A case report
As the most effective treatment for end-stage renal diseases, renal transplantation can improve the quality of life of patients and prolong the survival time. However, during the prolonged survival time, malignancy has become one of the main causes of death of recipients, which vary geographically....
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2020-10-01
|
Series: | Open Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1515/med-2020-0118 |
id |
doaj-bd118d76744e4cc6abe67d65a36137df |
---|---|
record_format |
Article |
spelling |
doaj-bd118d76744e4cc6abe67d65a36137df2021-10-02T17:50:26ZengDe GruyterOpen Medicine2391-54632020-10-0115198198510.1515/med-2020-0118med-2020-0118Endometrial cancer in a renal transplant recipient: A case reportLiu Na0Yang Lei1Long Yan2Jiang Guoqing3Department of Gynecology & Obstetrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong’an Road, Beijing 100050, ChinaDepartment of Gynecology & Obstetrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong’an Road, Beijing 100050, ChinaDepartment of Gynecology & Obstetrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong’an Road, Beijing 100050, ChinaDepartment of Gynecology & Obstetrics, Beijing Friendship Hospital, Capital Medical University, No. 95, Yong’an Road, Beijing 100050, ChinaAs the most effective treatment for end-stage renal diseases, renal transplantation can improve the quality of life of patients and prolong the survival time. However, during the prolonged survival time, malignancy has become one of the main causes of death of recipients, which vary geographically. Tumors in the digestive system and urothelial tumors have been highly reported in Asia. In general, the gynecological malignant tumors have been rarely reported, especially the endometrial carcinoma. Herein, a 63-year-old female renal transplant recipient diagnosed with endometrial carcinoma (15 years after transplantation) was reported. The patient had suffered irregular postmenopausal bleeding for a short time before hospitalization. She underwent abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic lymphadenectomy, right para-aortic lymphadenectomy and omental excision. Postoperative pathology showed ovarian and pelvic lymph node metastasis and pathological stage IIIC. After six courses of chemotherapy with paclitaxel 270 mg + carboplatin 500 mg, the patient’s renal function was normal. During the third cycle of chemotherapy, the patient suffered a third-degree bone marrow suppression and returned to normal soon when treated with the recombinant human granulocyte stimulating factor. In conclusion, early screening of gynecologic tumors is important for female patients after renal transplantation, which has a positive significance for the prognosis improvement.https://doi.org/10.1515/med-2020-0118renal transplantationendometrial carcinomachemotherapycase report |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Liu Na Yang Lei Long Yan Jiang Guoqing |
spellingShingle |
Liu Na Yang Lei Long Yan Jiang Guoqing Endometrial cancer in a renal transplant recipient: A case report Open Medicine renal transplantation endometrial carcinoma chemotherapy case report |
author_facet |
Liu Na Yang Lei Long Yan Jiang Guoqing |
author_sort |
Liu Na |
title |
Endometrial cancer in a renal transplant recipient: A case report |
title_short |
Endometrial cancer in a renal transplant recipient: A case report |
title_full |
Endometrial cancer in a renal transplant recipient: A case report |
title_fullStr |
Endometrial cancer in a renal transplant recipient: A case report |
title_full_unstemmed |
Endometrial cancer in a renal transplant recipient: A case report |
title_sort |
endometrial cancer in a renal transplant recipient: a case report |
publisher |
De Gruyter |
series |
Open Medicine |
issn |
2391-5463 |
publishDate |
2020-10-01 |
description |
As the most effective treatment for end-stage renal diseases, renal transplantation can improve the quality of life of patients and prolong the survival time. However, during the prolonged survival time, malignancy has become one of the main causes of death of recipients, which vary geographically. Tumors in the digestive system and urothelial tumors have been highly reported in Asia. In general, the gynecological malignant tumors have been rarely reported, especially the endometrial carcinoma. Herein, a 63-year-old female renal transplant recipient diagnosed with endometrial carcinoma (15 years after transplantation) was reported. The patient had suffered irregular postmenopausal bleeding for a short time before hospitalization. She underwent abdominal hysterectomy, bilateral salpingo-oophorectomy, right pelvic lymphadenectomy, right para-aortic lymphadenectomy and omental excision. Postoperative pathology showed ovarian and pelvic lymph node metastasis and pathological stage IIIC. After six courses of chemotherapy with paclitaxel 270 mg + carboplatin 500 mg, the patient’s renal function was normal. During the third cycle of chemotherapy, the patient suffered a third-degree bone marrow suppression and returned to normal soon when treated with the recombinant human granulocyte stimulating factor. In conclusion, early screening of gynecologic tumors is important for female patients after renal transplantation, which has a positive significance for the prognosis improvement. |
topic |
renal transplantation endometrial carcinoma chemotherapy case report |
url |
https://doi.org/10.1515/med-2020-0118 |
work_keys_str_mv |
AT liuna endometrialcancerinarenaltransplantrecipientacasereport AT yanglei endometrialcancerinarenaltransplantrecipientacasereport AT longyan endometrialcancerinarenaltransplantrecipientacasereport AT jiangguoqing endometrialcancerinarenaltransplantrecipientacasereport |
_version_ |
1716850422604365824 |